成人复发难治急性髓系白血病治疗进展
Advances in the Treatment of Adult Relapsed/Refractory Acute Myeloid Leukemia
摘要: 成人复发/难治急性髓细胞白血病治疗仍面临较大困难，目前尚无统一、有效的治疗方案。患者预后极差，传统的挽救性化疗缓解率较低，并且患者因为原发耐药、药物累积的毒性作用、脏器功能衰退、干细胞储备功能低、家庭经济等诸多因素，常常限制了治疗方案的选择。随着对白血病生物学特性认识的不断深入，一系列与AML发病机制和病理生理密切相关的基因、受体、抗原、细胞内关键物质等相继被发现，使得复发/难治急性髓系白血病的治疗有了更多的选择。目前针对复发难治急性髓系白血病的治疗有传统化疗、造血干细胞移植、靶向治疗、免疫治疗等。本人针对成人复发/难治急性髓系白血病治疗进展做一综述。
Abstract: The treatment of adult relapsed/refractory acute myeloid leukemia still faces great difficulties, and there are no unified and effective treatment solutions. The prognosis of patients is extremely poor, and the remission rate of traditional salvage chemotherapy is low. Additionally, the choice of a treatment plan is limited due to primary drug resistance, toxic effects of accumulated drugs, decline in organ function, low stem cell reserve, family economy, and other factors. With the expansion in the understanding of the biological characteristics of leukemia, a series of genes, receptors, antigens, and key intracellular substances that are closely related to the pathogenesis and pathophysiology of AML have been discovered. This has provided more options for the treatment of relapsed/refractory acute myeloid leukemia. Current treatments for relapsed and refractory acute myeloid leukemia include traditional chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy. In this paper, we will review the progress in the treatment of adult relapsed/refractory acute myeloid leukemia.
文章引用：杨明婷, 何丽娟, 张秋蓉, 李永萍. 成人复发难治急性髓系白血病治疗进展[J]. 临床医学进展, 2021, 11(1): 24-33. https://doi.org/10.12677/ACM.2021.111004

参考文献

[1] Kiyoi, H. (2019) Acute Myeloid Leukemia: AML. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 60, 224-225.
[2] Rallig, C. (2019) Diagnosis and Treatment of Acute Myeloid Leukemia: The Updated 2018 Onkopedia Guideline. Der Internist, 60, 257-272. [Google Scholar] [CrossRef] [PubMed]
[3] Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association (2017) Chinese Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Not APL) (2017). Chinese Journal of Hematology, 38, 177-182.
[4] Tallman, M.S., Wang, E.S., Altman, J.K., et al. (2019) Acute Myeloid Leukemia, Version 3. 2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 721-749.
[5] Othus, M., Appelbaum, F.R., Petersdorf, S.H., et al. (2015) The Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. Biology of Blood and Marrow Transplantation, 21, 559-564. [Google Scholar] [CrossRef] [PubMed]
[6] Fernadez, H.F., Sun, Z., Yao, X., et al. (2009) Anthracycline Dose Intensification in Acute Myeloid Leukemia. New England Journal of Medicine, 361, 1249-1259. [Google Scholar] [CrossRef] 
[7] Lowenberg, B., Ossenkoppele, G.H., van Putten, W., et al. (2009) High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. New England Journal of Medicine, 361, 1235-1248. [Google Scholar] [CrossRef] 
[8] Estey, E. (2016) Why Are There So Few Randomized Trials for Patients with Primary Refractory Acute Myeloid Leukemia. Best Practice & Research Clinical Haematology, 29, 324-328. [Google Scholar] [CrossRef] [PubMed]
[9] Kell, J. (2016) Considerations and Challenges for Patients with Refractory and Relapsed Acute Myeloid Leukaemia (Review). Leukemia Research, 47, 149-160. [Google Scholar] [CrossRef] [PubMed]
[10] 马立元. 成人复发难治性急性髓系白血病治疗进展[J]. 医学与哲学(B), 2018, 39(8): 20-24.
[11] O’Donnell, M.R., Tallman, M.S., Abboud, C.N., et al. (2017) Acute Myeloid Leukemia, Version 3. 2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 926-957.
[12] Sternberg, D.W., Aird, W., Neuberg, D., et al. (2000) Treatment of Patients with Recurrent and Primary Refractory Acute Myelogenous Leukemia Using Mitoxantrone and Intermediate-Dose Cytarabine: A Pharmacologically Based Regimen. Cancer, 88, 2037-2041. [Google Scholar] [CrossRef] 
[13] Breems, D.A., Van Putten, W.L., Huijgens, P.C., et al. (2005) Prognostic Index for Adult Patients with Acute Myeloid Leukemia in First Relapse. Journal of Clinical Oncology, 23, 1969-1978. [Google Scholar] [CrossRef] 
[14] Wierzbowska, A., Robak, T., Pluta, A., et al. (2008) Cladribine Combined with High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) Is a Highly Effective Salvage Regimen in Patients with Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group. European Journal of Haematology, 80, 115-126. [Google Scholar] [CrossRef] [PubMed]
[15] Keating, M.J., Kantarjian, H., Smith, T.L., et al. (1989) Response to Salvage Therapy and Survival after Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 7, 1071-1080. [Google Scholar] [CrossRef] 
[16] Gupta, N., Wang, E.S., Freyer, C.W., et al. (2015) Revisiting the Role of Cladribine in Acute Myeloid Leukemia: An Improvement on Past Accomplishments or More Old News? American Journal of Hematology, 90, 62-72. [Google Scholar] [CrossRef] [PubMed]
[17] Robak, T. and Wierzbowska, A. (2014) Cladribine in the Treatment of Acute Myeloid Leukemia. Leukemia Research, 38, 425-427. [Google Scholar] [CrossRef] [PubMed]
[18] 陈思思, 赵慧慧, 黄佳瑜, 等. CLAG为基础的挽救化疗方案治疗复发难治急性髓系白血病临床观察[J]. 白血病(淋巴瘤), 2019, 28(9): 556-559.
[19] (2020) Fludarabine. Lethal Bone Marrow Suppression: Case Report. Reactions Weekly, 1787, 237. [Google Scholar] [CrossRef] 
[20] 赵兰滨, 申莲玉. 中剂量阿糖胞苷的FLAG方案治疗难治复发性急性髓系白血病12例临床观察[J]. 中外健康文摘, 2013(4): 135-136.
[21] 周茉, 单学赟. CLAG方案和MEA方案治疗复发/难治急性髓系白血病的疗效比较[J]. 系统医学, 2018, 3(14): 24-25, 28.
[22] 刘祥祥, 张涛, 王健红, 等. FLAG和MEA方案治疗难治复发性急性髓系白血病的Meta分析[J]. 现代肿瘤医学, 2019, 27(4): 636-640.
[23] 罗文丰, 余惠兰, 邹兴立, 等. CLAG方案和FLAG方案治疗难治或复发性急性髓系白血病对比观察[J]. 山东医药, 2018, 58(40): 73-76.
[24] 刘建平, 郄丽萍, 王向文. 大剂量阿糖胞苷治疗急性白血病的临床观察[J]. 内蒙古医学杂志, 2007, 39(8): 942-943.
[25] Christian, S., Patel, P., Esen, A., et al. (2017) A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) vs High-Dose Cytarabine and Mitoxantrone (ARA-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 130, 2591. [Google Scholar] [CrossRef] 
[26] 陈妍, 陈加华. 预激方案治疗低增生性及复发与难治的急性髓系白血病36例临床观察[J]. 中国实用内科杂志, 2012, 32(A2): 24-25.
[27] 卓丽霞. 地西他滨联合CAG方案治疗难治、复发性急性髓系白血病的疗效观察[J]. 中国实用医药, 2020, 15(5): 149-151.
[28] 祖璎玲, 张莉, 周健, 等. CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析[J]. 中华血液学杂志, 2016, 37(4): 334-336.
[29] 陈琳, 米瑞华, 朱松涛, 等. 西达本胺、地西他滨联合CHAG方案治疗复发难治性急性髓系白血病八例疗效分析[J]. 中华血液学杂志, 2018, 39(7): 602-604.
[30] 范翠华, 俞文娟, 麦文渊, 等. HAA方案治疗复发难治性急性髓系白血病64例疗效观察[J]. 中华血液学杂志, 2016, 37(2): 100-104.
[31] 徐玉秀. HAD方案治疗难治复发性急性髓系白血病的疗效观察[J]. 中国实用医药, 2013, 8(15): 78-79.
[32] Khan, N., Hantel, A., Knoebel, et al. (2017) Efficacy of Single-Agent Decitabine in Relapsed and Refractory Acute Myeloid Leukemia. Leukemia and Lymphoma, 58, 2127-2133. [Google Scholar] [CrossRef] [PubMed]
[33] Ivanoff, S., Gruson, B., Chantepie, S.P., et al. (2013) 5-Azacytidine Treatment for Relapsed or Refractory Acute Myeloid Leukemia after Intensive Chemotherapy. American Journal of Hematology, 88, 601-605. [Google Scholar] [CrossRef] [PubMed]
[34] Schmidt, E., Mikesch, J.-H., Groth, C., et al. (2017) Allogeneic Transplantation in the Treatment of Acute Leukemia (Review). Onkologe, 23, 543-549. [Google Scholar] [CrossRef] 
[35] Bose, P., Vachhani, P. and Cortes, J.E. (2017) Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Current Treatment Options in Oncology, 18, 17. [Google Scholar] [CrossRef] [PubMed]
[36] Su, X.H., Yao, J.F., Zhang, G.X., et al. (2017) Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Refractory and Relapsed Acute Myeloid Leukemia: Outcomes and Prognostic Factors. Chinese Journal of Hematology, 38, 1024-1030.
[37] Vasu, S., Kohlschmidt, J., Mrozek, K., et al. (2018) Ten-Year Outcome of Patients with Acute Myeloid Leukemia Not Treatment with Allogeneic Transplantation in First Complete Remission. Blood Advances, 2, 1645-1650. [Google Scholar] [CrossRef] [PubMed]
[38] Tian, H., Chen, G.H., Xu, Y., et al. (2015) Impact of Pre-Transplant Disease Burden on the Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Refractory and Relapsed Acute Myeloid Leukemia: A Single-Center Study. Leukemia & Lymphoma, 56, 1353-1361. [Google Scholar] [CrossRef] [PubMed]
[39] Todisco, E., Cieefi, F., Boschini, et al. (2017) Factors Predicting Outcome after Allogeneic Transplant in Refractory Acute Myeloid Leukemia: A Retrospective Analysis of Grnppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant, 52, 955-961. [Google Scholar] [CrossRef] [PubMed]
[40] 董征, 胡锴勋, 余长林, 等. 单倍体非清髓造血干细胞移植治疗难治复发性白血病的长期随访结果[J]. 中华血液学杂志, 2013, 34(3): 217-220.
[41] Smith, C.C. (2019) The Growing Landscape of FLT3 Inhibition in AML. Hematology. American Society of Hematology. Education Program, 2019, 539-547. [Google Scholar] [CrossRef] [PubMed]
[42] Leick, M.B. and Levis, M.J. (2017) The Future of Targeting FLT3 Activation in AML. Current Hematologic Malignancy Reports, 12, 153-167. [Google Scholar] [CrossRef] [PubMed]
[43] Antar, A.I., Otrock, Z.K., Jabbour, E., et al. (2020) FLT3 Inhibitors in Acute Myeloid Leukemia: Ten Frequently Asked Questions. Leukemia, 34, 682-696. [Google Scholar] [CrossRef] [PubMed]
[44] Robert, R. (2020) The Role of Small Molecule Flt3 Receptor Protein-Tyrosine Kinase Inhibitors in the Treatment of Flt3-Positive Acute Myelogenous Leukemias. Pharmacological Research, 155, Article ID: 104725. [Google Scholar] [CrossRef] [PubMed]
[45] Perl, A. (2018) FLT3 Inhibitors in AML. Clinical Lymphoma, Myeloma & Leukemia, 18, S1-S2. [Google Scholar] [CrossRef] 
[46] Zhang, W., Konopleva, M., Shi, Y., et al. (2008) Mutant FLT3: Sorafenib in Acute Myelogenous Leukemia. Journal of the National Cancer Institute, 100, 184-198. [Google Scholar] [CrossRef] [PubMed]
[47] Zhang, Y., Xuan, L., Fan, Z.P., et al. (2016) Sorafenib as Salvage Therapy in Refractory Relapsed Acute Myeloid Leukemia with Positive FLT3 Mutation. Chinese Journal of Hematology, 37, 292-296.
[48] Ravandi, F., Alattar, M.L., Grunwald, M.R., et al. (2013) Phase 2 Study of Azacytidine plus Sorafenib in Patients with Acute Myeloid Leukemia and FLT-3 Internal Tandem Duplication Mutation. Blood, 121, 4655-4662. [Google Scholar] [CrossRef] [PubMed]
[49] Nazha, A., Kantarjian, H.M., Borthakur, G., et al. (2012) A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 120, 3587. [Google Scholar] [CrossRef] 
[50] Levis, M., Ravandi, F., Wang, E.S., et al. (2011) Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for Patients with FLT3 Mutant AML in First Relapse. Blood, 117, 3294-3301. [Google Scholar] [CrossRef] [PubMed]
[51] Usuki, K., Handa, H., Choi, I., et al. (2019) Safety and Pharmacokinetics of Quizartinib in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia in a Phase 1 Study. International Journal of Hematology, 110, 654-664. [Google Scholar] [CrossRef] [PubMed]
[52] Inaba, H., Panetta, J.C., Buelow, D.R., et al. (2016) Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. Blood, 128, 3937. [Google Scholar] [CrossRef] 
[53] Reed, D.R., Sen, J.M., Pierce, E.J., et al. (2020) Gilteritinib: An FMS-Like Tyrosine Kinase 3/AXL Tyrosine Kinase Inhibitor for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients. Journal of Oncology Pharmacy Practice, 26, 1200-1212. [Google Scholar] [CrossRef] [PubMed]
[54] Mata, R., Subirá, D., García-Raso, A., et al. (2007) Jak2 as a Molecular Marker in Myeloproliferative Diseases. Cardiovascular and Hematological Agents in Medicinal Chemistry, 5, 198-203. [Google Scholar] [CrossRef] [PubMed]
[55] Lee, H.J., Daver, N., Kantarjian, H.M., et al. (2013) The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 19, 327-335. [Google Scholar] [CrossRef] 
[56] Pemmaraju, N., Kantarjian, H., Kadia, T, et al. (2015) A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 15, 171-176. [Google Scholar] [CrossRef] [PubMed]
[57] Kelly, A.D., Madzo, J., Madireddi, P., et al. (2018) Demethylator Phenotypes in Acute Myeloid Leukemia. Leukemia, 32, 2178-2188. [Google Scholar] [CrossRef] [PubMed]
[58] Zhu, C.-Y., et al. (2015) Clinical Research of Decitabine Combined with Modified CAG Regimen for Treatment of Relapsed or Refractory Acute Myeloid Leukemia. Chinese Journal of Experimental Science, 23, 88-93.
[59] Dang, L., Yen, K. and Attar, E.C. (2016) IDH Mutations in Cancer and Progress toward Development of Targeted Therapeutics. Annals of Oncology, 27, 599-608. [Google Scholar] [CrossRef] [PubMed]
[60] Mondesir, J., Willekens, C., Touat, M., et al. (2016) IDH1 and IDH2 Mutations as Novel Therapeutic Targets: Current Perspectives. Journal of Blood Medicine, 7, 171-180. [Google Scholar] [CrossRef] 
[61] Stein, E.M., DiNardo, C.D., Pollyea, D.A., et al. (2017) Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia. Blood, 130, 722-731. [Google Scholar] [CrossRef] [PubMed]
[62] Medeiros, B.C., Fathi, A.T., DiNardo, C.D., et al. (2017) Isocitrate Dehydrogenase Mutations in Myeloid Malignancies. Leukemia, 31, 272-281. [Google Scholar] [CrossRef] [PubMed]
[63] Lagadinou, E.D., Sach, A., Callahan, K., et al. (2013) BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. Cell Stem Cell, 12, 329-341. [Google Scholar] [CrossRef] [PubMed]
[64] DiNardo, C.D., Pratz, K., Pullarkat, V., et al. (2018) Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia. Blood, 133, 7-17.
[65] Lehmann, C., Friess, T., Birzele, F., et al. (2016) Superior Anti-Tumor Activity of the MDM2 Antagonist Idasanutlin and the Bcl-2 Inhibitor Venetoclax in p53 Wild-Type Acute Myeloid Leukemia Models. Journal of Hematology & Oncology, 9, 50. [Google Scholar] [CrossRef] [PubMed]
[66] Atrash, S., Bano, K., Harrison, B., et al. (2020) CAR-T Treatment for Hematological Malignancies. Journal of Investigative Medicine. [Google Scholar] [CrossRef] [PubMed]
[67] Porter, D.L., Levine, B.L., Kalos, M., et al. (2011) Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine, 365, 725-733. [Google Scholar] [CrossRef] 
[68] Davila, M.L., Riviere, I., Wang, X., et al. (2014) Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 6, 224ra25.
[69] Rahal, I., Cabannes-Hamy, A. and Boissel, N. (2018) CAR-T Treatment of Acute Leukemia in Adults. Bulletin du Cancer, 105, S158-S167. [Google Scholar] [CrossRef] 
[70] Kim, M.Y., Yu, K.-R., Kenderian, S.S., et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 173, 1439-1453.e19.
[71] Galetto, R., Lebuhotel, C., Francon, P., et al. (2015) Allogenic CAR T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML). Molecular Therapy, 23, S166. [Google Scholar] [CrossRef] 
[72] Wang, Q.S., Wang, Y., Lv, H.-Y., et al. (2015) Treatment of CD33-Directed Chimeric Antigen Receptor-Modified T Cells in One Patient with Relapsed and Refractory Acute Myeloid Leukemia. Molecular Therapy, 23, 184-191. [Google Scholar] [CrossRef] [PubMed]
[73] Budde, L., Song, J.Y. and Kim, Y. (2017) Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. Blood, 130, 811.

为你推荐